Literature DB >> 35570184

Investigation of a cluster of Legionnaires' disease during the outbreak of coronavirus disease 2019 pandemic in northeastern Taiwan, June 2021.

Jung-Jr Ye1, Jun-Yuan Zheng2, Ya-Hsuan Chen3, Ya-Ling Kao4, Yu-Chin Kao5, Shao-Wen Chao6.   

Abstract

PURPOSE: To describe the investigation and intervention of a cluster of Legionnaires' disease detected during the outbreak of coronavirus disease 2019 (COVID-19) pandemic.
METHODS: From June 7 to 22, 2021, 15 cases in the neighborhood near our hospital were detected. Information about residence, workplace, hospital visit, and potential exposures was collected. Sampling and decontamination were performed for potential sources.
RESULTS: All 15 patients had pneumonia when visiting the emergency room with negative COVID-19 test results. Most patients were male (73.3%) with the mean age of 65.7 years. The most common comorbidities were diabetes mellitus (40.0%) and hypertension (40%). The most common symptom was fever (93.3%). Two (13.3%) patients needed mechanical ventilators. Fever subsided within 2 days of treatment for most cases (85.7%). Five cases had exposure history at our hospital, and the other 10 lived or worked in the area within 2 km of our hospital, mostly in buildings A and B. Water sampling was carried out for our hospital, buildings A and B; one water sample from a cooling tower in our hospital cultured positive for Legionella bacteria. Early testing and treatment for suspected cases were carried out for the outbreak, and all cases were discharged with pneumonia resolution.
CONCLUSION: This was a community outbreak of Legionnaires' disease near our hospital. COVID-19 tests were repeated frequently before testing for Legionnaires' disease during the COVID-19 pandemic. Early recognition of Legionnaires' disease and timely treatment improved outcome.
Copyright © 2022. Published by Elsevier B.V.

Entities:  

Keywords:  COVID-19; Legionnaires' disease; Pneumonia

Year:  2022        PMID: 35570184      PMCID: PMC9068600          DOI: 10.1016/j.jmii.2022.04.008

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   10.273


Introduction

Legionnaires' disease was first identified in 1976 in a pneumonia outbreak among American Legion members attending their annual meeting in Philadelphia. Infection occurs through inhalation of aerosols containing Legionella bacteria. The most frequently identified species isolated from patients with Legionnaires’ disease was Legionella pneumophila serogroup 1, which has been recognized as an important cause of both hospital and community-acquired pneumonia. A prior epidemiological study of L. pneumophila infection in Taiwan reported an incidence rate of 4.7% among pneumonia patients. In a retrospective study of Legionnaires' disease in a 1200-bed tertiary hospital in southern Taiwan, 61 cases were identified over a 9-year period. Among them, 30 (49.2%) and 20 (32.8%) had healthcare-associated and community-acquired pneumonia, respectively, including 11 (18.0%) caregivers. Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in December 2019. The disease rapidly became an ongoing pandemic crisis worldwide. The pandemic had a smaller impact in Taiwan in 2020 than in most other countries; however, an outbreak in northern Taiwan occurred in May 2021, resulting in more than 15,000 confirmed cases with more than 800 deaths within the following three months. In June 2021, we detected a cluster of Legionnaires' disease during the COVID-19 pandemic. From June 7 to 22, 2021, 15 Legionnaires’ disease cases were detected in individuals living or working in the neighborhood near our hospital, including two hospital staff members. This number was three times that observed in our hospital in the previous 3 years combined, including 2 cases, 2 cases, and 1 case detected in 2018, 2019, and 2020, respectively (JJ Ye, unpublished data). This study aimed to determine whether this cluster was a nosocomial or community outbreak, investigate the potential sources, and analyze the clinical features, control measures and outcomes.

Methods

Study design, setting and patients

This retrospective study was conducted at Chang Gung Memorial Hospital (CGMH)-Keelung branch, which is a 1100-bed regional teaching hospital providing both primary and tertiary health care in northeastern Taiwan. The study protocol was approved by the Institutional Review Board of CGMH-Keelung branch (Number: 202101475B0). The ethics committee granted a waiver for informed consent to be obtained from patients because the existing medical data and investigation reports were analyzed anonymously and maintained with confidentiality. Legionnaires' disease was defined as a new or progressive pulmonary infiltrate on chest radiography, along with the presence of symptoms and signs of lower respiratory tract infection, and a positive result for the urinary Legionella antigen test. A commercial urine antigen test (Abbott BinaxNOW Legionella urinary antigen test kit; Abbott Laboratories, Irvine, CA, USA) was used to detect the L. pneumophila serogroup 1 soluble antigen. Patients’ medical records were reviewed for demographic and clinical data, including comorbidities, symptoms, clinical course, laboratory data, oxygen use, treatment, and outcomes. Delayed treatment was defined as initiation of antibiotic treatment with anti-Legionella activity after the second day of hospitalization.

Epidemiological investigations

The epidemiological investigations were performed by the Infection Control Team of CGMH-Keelung as soon as possible after a diagnosis was confirmed. Each patient was interviewed by phone to collect information about residence, profession, workplace, and potential exposures (including travel, hospital visit, spa/pool, fountains, grocery stores, drinking water supply issues, car washes, and aerosol-generating devices or equipment) within 14 days prior to symptom onset. The data of urinary Legionella antigen test in the previous 5 years, and the number of confirmed COVID-19 cases with positive reverse transcription-polymerase chain reaction (RT-PCR) test based on nasopharyngeal swabs in our hospital from April to July 2021 were collected and analyzed.

Environmental investigations

Routine testing for Legionella bacteria with culture and free residual chlorine in water was performed in our hospital every six months for cooling towers and the water supply system in transplant wards, and annually for other water supply systems. A 300 ml water sample was collected from selected sites for culture and testing. The most recent routine testing prior to the reported Legionnaires’ disease outbreak was performed in April 2020, and all water samples were negative for Legionella bacteria. To investigate potential sources of the reported cluster of Legionnaires' disease, water sampling was carried out by the Infection Control Team of CGMH-Keelung for our hospital and administrative office (on second floor of building A) on June 16, 2021, and by the Health Department, Keelung City, for other places on June 21, 25, and 30, 2021. Twenty samples collected in our hospital and administrative office included 8 water samples from water cooling towers, 4 from cisterns, 4 from faucets in toilets, 2 from water dispensers, and 2 swab samples from air conditioner vents. Thirty-six water samples from building A included 2 from water cooling towers, 17 from cisterns; 9 from garden ponds, fountains, and sprinklers; 5 from bathrooms and 3 from water dispensers. Four water samples from building B included 1 from a garden pond and 3 from cisterns. Each sample was cultured on the media of buffered charcoal yeast extract (BCYE) agar. Colonies suspected to be Legionella were incubated on BCYE agar with l-cysteine. Microscopic examination was used to verify suspect colonies. Identification of isolates was performed using Matrix-assisted laser desorption/ionization–time-of-flight mass spectrometry (MALDI-TOF MS, Autoflex II; Bruker Daltonics, Germany) and MALDI Biotyper 3.1 database system. Samples from our hospital and administrative office were also tested with RT-PCR targeting major intrinsic protein (MIP) gene.

Results

Clinical presentation and outcomes

All patients presented with pneumonia on chest radiograph when arriving at the emergency room (ER), and were then admitted to wards for treatment. Most patients were male (73.3%) with mean age 65.7 years. The most common concomitant diseases were diabetes mellitus (40.0%) and hypertension (40%). Fourteen patients had no smoking history and one had quit smoking years earlier. The most common symptom was fever (93.3%), followed by cough (66.7%) and gastrointestinal upset (26.7%) (Table 3). The days from symptom onset to hospital visit ranged from 1 to 5 days, with mean 2.3 days (Table 1, Table 3 ). Five (33.3%) patients had bilateral pneumonia and 13 patients had mean C-reactive protein (CRP) of 226.0 mg/L. Other abnormal laboratory data included hyponatremia (60%), elevated liver enzymes (40%) and leukocytosis (40%). Three patients used O2 masks and two used mechanical ventilators (Table 3). The days from hospitalization to diagnosis ranged from 1 to 9 days with mean 3.5 days (Table 2, Table 3). One patient with 9 days until diagnosis had end-stage renal disease with insufficient urine for urinary antigen test. Thirteen cases were treated with levofloxacin, two received azithromycin for pneumonia treatment, and four (26.7%) received delayed treatment. Fever subsided within two days of treatment for most cases (12/14, 85.7%) and all patients were discharged with resolution of pneumonia (Table 3). The hospital stays ranged from three to 58 days with mean 13.7 days (Table 2, Table 3). All cases had at least two negative COVID-19 RT-PCR test results based on nasopharyngeal swabs. Nine cases had sputum cultures and all showed growth of normal flora (Table 2).
Table 3

Clinical characteristics, treatment, and outcomes of the 15 cases.

CharacteristicsValuea
Demographic parameters
 Age, years65.7 ± 13.6
 Male/Female11/4
Underlying diseases
 Diabetes mellitus6 (40.0)
 Hypertension6 (40.0)
 Hyperlipidemia4 (26.7)
 Malignancy2 (13.3)
 End stage renal disease1 (6.7)
Symptoms
 Fever14 (93.3)
 Cough10 (66.7)
 Gastrointestinal upset4 (26.7)
Onset to visit hospital, days2.3 ± 1.2
Clinical conditions
 Bilateral pneumonia5 (33.3)
 C-reactive protein, mg/L (n = 13)226.0 ± 91.1
 Leukocytosis6 (40.0)
 Thrombocytopenia3 (20.0)
 Hyponatremia9 (60.0)
 Acute renal insufficiency5 (33.3)
 Increasing liver enzymes6 (40.0)
Oxygen use
 Nasal cannula9 (60.0)
 Simple mask3 (20.0)
 Mechanical ventilator2 (13.3)
Hospitalization to diagnosis, days3.5 ± 2.4
Treatment
 Delayed treatment4 (26.7)
 Levofloxacin treatment13 (86.7)
 Treatment to defervescence >2 days2 (13.3)
 Days of hospitalization13.7 ± 13.5
Outcomes
 Discharge15 (100.0)
 Resolution of pneumonia15 (100.0)

Categorical data are no. (%) of subject, continuous data are expressed as means ± standard deviations.

Table 1

Demographic and clinical characteristics of each case.

CaseAge (y)SexUnderlying diseasesSymptomsOnset to ER (d)Chest radiograph findingsOther abnormal laboratory data (blood sample)Oxygen use
167MaleDM, hypertension, gout, hypothyroidismFever, cough, conscious change2RUL consolidationCreatinine: 1.82 mg/dLSodium: 132 meq/LPlatelet count: 88000/uLNasal cannula
263MaleOld stroke, CML, Hypertension, hyperlipidemiaFever2LUL, LLL, RLL consolidationCRP: 201 mg/LAST:108 U/LTotal bilirubin: 1.4 mg/dLSodium: 126 meq/LWBC: 15300/uLMechanical ventilator
351MaleDM, hyperlipidemiaFever, headache, general soreness3RUL, LLL consolidationCRP: 342 mg/LTotal bilirubin: 1.7 mg/dLALT: 122 U/LWBC: 13100/uLNasal cannula
452MaleDM, hypertensionFever, diarrhea, vomiting3RUL, RLL consolidationCRP: 272 mg/LCreatinine: 2.49 mg/dLSodium: 132 meq/LWBC: 14500/uLSimple mask
573MaleNoneFever, cough3RUL, LUL consolidationCRP: 300 mg/LCreatinine: 4.76 mg/dLSodium: 132 meq/LWBC: 13900/uLPlatelet count: 104000/uLMechanical ventilator
645MaleDM, ESRD, HypertensionFever, vomiting1Bilateral lung infiltrationCRP: 149 mg/LSodium: 124 meq/LWBC: 12200/uLSimple mask
754MaleHyperlipidemiaFever, diarrhea, vomiting3LLL consolidationCRP: 229 mg/LALT: 145 U/LSodium: 131 meq/LNasal cannula
865FemaleNoneFever, cough5RLL cosolidationCRP: 338 mg/LALT: 89 U/LNasal cannula
966FemaleDMCough, dyspnea1RUL, RLL, LLL consolidationALT: 86 U/LWBC: 12100/uLNasal cannula
1089MaleHypertensionFever, cough, sore throat4RUL, RLL consolidationCRP: 170 mg/LCreatinine: 1.58 mg/dLNone
1191MaleProstate cancerFever, cough2RUL consolidationCRP: 227 mg/LCreatinine: 1.58 mg/dLSodium: 132 meq/LPlatelet count: 123000/uLNasal cannula
1261FemaleHyperlipidemiaFever, epigastric pain, cough1RLL consolidationCRP: 146 mg/LSodium: 128 meq/LNasal cannula
1356MaleDMFever, cough2LUL consolidationCRP: 326 mq/LSodium: 125 meq/LNasal cannula
1481MaleHypertension, CADFever, cough, sore throat1LUL consolidationCRP: 27 mg/LSimple mask
1572FemaleHand tremorFever, cough1RLL consolidationCRP: 211 mq/LALT: 63 U/LNasal cannula

Abbreviations: ER, emergency room; DM, diabetes mellitus; RUL, right upper lobe; CML, chronic myeloid leukemia; LUL, left upper lobe; LLL, left lower lobe; RLL, right lower lobe; CRP, C-reactive protein; AST, aspartate aminotransferase; WBC, white blood cell count; ESRD, end stage renal disease; CAD, coronary artery disease.

Table 2

Diagnosis, treatment, and outcome of each case.

caseHospitalization to diagnosis (d)Other microbiological testsTreatment initiationRegimensTreatment to defervescence (d)Days of hospitalizationOutcomePneumonia follow-up
12COVID-19 (−) × 2Sputum culture: normal floraDay 1Levofloxacin121DischargeResolution
27COVID-19 (−) × 2Sputum culture: normal flora Sputum PJP PCR test (−)Serum Aspergillus antigen (−)Day 3Levofloxacin321DischargeResolution
35COVID-19 (−) × 3Day 1Azithromycin17DischargeResolution
45COVID-19 (−) × 2Influenza rapid antigen (−)Day 4Levofloxacin514DischargeResolution
54COVID-19 (−) × 2Sputum culture: normal floraDay 2Levofloxacin158DischargeResolution
69COVID-19 (−) × 3Serum Cryptococcal antigen (−)Day 5Levofloxacin211DischargeResolution
71COVID-19 (−) × 3Influenza rapid antigen (−)Day 2Levofloxacin28DischargeResolution
81COVID-19 (−) × 3Day 1Levofloxacin17DischargeResolution
93COVID-19 (−) × 3Sputum culture: normal floraDay 1Levofloxacin.7DischargeResolution
102COVID-19 (−) × 3Sputum culture: normal floraDay 1Azithromycin13DischargeResolution
115COVID-19 (−) × 3Sputum culture: normal floraDay 5Levofloxacin116DischargeResolution
122COVID-19 (−) × 2Day 2Levofloxacin16DischargeResolution
134COVID-19 (−) × 2Sputum culture: normal floraDay 1Levofloxacin112DischargeResolution
142COVID-19 (−) × 2Sputum culture: normal floraDay 1Levofloxacin111DischargeResolution
151COVID-19 (−) × 2Sputum culture: normal floraDay 1Levofloxacin13DischargeResolution

Abbreviations: COVID-19, Coronavirus disease 2019; PJP, Pneumocystis Jiroveci pneumonia; PCR, polymerase chain reaction.

Demographic and clinical characteristics of each case. Abbreviations: ER, emergency room; DM, diabetes mellitus; RUL, right upper lobe; CML, chronic myeloid leukemia; LUL, left upper lobe; LLL, left lower lobe; RLL, right lower lobe; CRP, C-reactive protein; AST, aspartate aminotransferase; WBC, white blood cell count; ESRD, end stage renal disease; CAD, coronary artery disease. Diagnosis, treatment, and outcome of each case. Abbreviations: COVID-19, Coronavirus disease 2019; PJP, Pneumocystis Jiroveci pneumonia; PCR, polymerase chain reaction. Clinical characteristics, treatment, and outcomes of the 15 cases. Categorical data are no. (%) of subject, continuous data are expressed as means ± standard deviations. Symptom onset date of cases are shown in Fig. 1 . The dates of diagnosis are shown in Fig. 2 . First case was detected on June 7, 2021 and the last case on June 22, 2021. During this period, the positive rate of urinary Legionella antigen test was 19.2% (15/78, Fig. 2). From 2016 to 2020, 8 positive cases were detected among 372 patients who were tested for urinary Legionella antigen in our hospital (2.2%). Ten patients (66.7%) lived or worked in buildings A and B, located within 200 and 100 m from our hospital, respectively (Fig. 3 ). Among them, three patients (cases 1, 11, 12) living in building A, and five patients (cases 2, 4, 5, 9, 10) living or working in building B, had no exposure history in our hospital within 14 days prior to symptom onset. The other two patients (cases 3, 7) were our staff members working at the administrative office on the second floor of building A and in our hospital. Three patients (cases 6, 13, 14) did not live near our hospital, but had regular hemodialysis or outpatient clinic visits within 14 days in our hospital. Two patients (cases 8, 15) had no hospital visit history and lived in places within 750 m and 1800 m from our hospital. In conclusion, 5 cases had exposure history in our hospital, and the other 10 cases lived or worked within two kilometers from our hospital (Fig. 3). The numbers of confirmed COVID-19 cases were 0, 67, 45, and 8 in April, May, June, and July 2021, respectively. The COVID-19 outbreak occurred in May 2021, and the pandemic was controlled gradually within the following months.
Figure 1

Symptom onset date of the 15 cases of Legionnaires' disease.

Figure 2

Cases tested with urinary Legionella antigen test from 7 to 30 June 2021, and the results.

Figure 3

The cases of Legionnaires' disease and their locations. a Case 3, 7 were our staff members and case 6, 13, 14 were our regular patients. b Case 1, 11, 12 lived or worked in building A and case 2, 4, 5, 9, 10 in build B, with no visit history of our hospital in prior 14 days. c Case 8, 15 had no visit history of our hospital in prior 14 days.

Symptom onset date of the 15 cases of Legionnaires' disease. Cases tested with urinary Legionella antigen test from 7 to 30 June 2021, and the results. The cases of Legionnaires' disease and their locations. a Case 3, 7 were our staff members and case 6, 13, 14 were our regular patients. b Case 1, 11, 12 lived or worked in building A and case 2, 4, 5, 9, 10 in build B, with no visit history of our hospital in prior 14 days. c Case 8, 15 had no visit history of our hospital in prior 14 days.

Environmental investigations, and interventions

Three water samples from cooling towers in our hospital had positive Legionella PCR tests, and one had a positive culture with 130 colony-forming units/liter of Legionella spp. One water sample from the cooling tower in our administration office in building A had positive Legionella PCR test with no Legionella bacteria growth on culture. The screening of Legionnaires' disease with urine antigen test for all pneumonia patients in the ER or wards was performed when the outbreak of Legionnaires' disease was first observed (3 cases on June 15, 2021, Fig. 2). We also advised clinical physicians, in online conferences or meetings, to administer levofloxacin or azithromycin early for suspected cases before Legionnaires' disease was confirmed. Decontamination was carried out for the water cooling towers and cisterns in our hospital on June 17, 2021, and for water systems in other buildings later. The cooling towers were shut down and sodium hypochlorite was added to keep free residual chlorine of at least 5–15 mg/L for at least 1 h. After the disinfection period, the cooling tower water was drained into waste disposal, and all accessible system equipment was physically cleaned. Then the system was refilled with clean water, the recirculating pump was switched on, and sodium hypochlorite was added again. The system was drained after the disinfection period and refilled. Finally, we reinstated comprehensive effective water treatment, including use of biocide, and returned the control equipment to normal operation. Legionella testing with culture was performed for cooling towers after decontamination, and the results were uniformly negative. From June 23 to 30, 2021, 49 patients were tested for Legionnaires' disease, and all results were negative (Fig. 2).

Discussion

This study reports a 15-case cluster of Legionnaires' disease occurring over a 16-day period in June 2021 during the COVID-19 pandemic. The case numbers and positive rate of urinary Legionella antigen tests significantly exceeded those noted during ordinary times. All patients diagnosed with Legionnaires' disease had pneumonia before admission. Some cases were hospital staff members or regular patients, and most patients lived or worked within 2 km of our hospital without exposure history in our hospital within 14 days prior to symptom onset. Based on the sharp surge in Legionnaires’ cases, the geographic clustering, and the investigation of environmental exposures, a community outbreak was determined. Some previous community outbreaks of Legionnaires' disease were associated with water cooling tower systems,8, 9, 10 which may transmit bacteria for miles; however, a definitive infection source is not always found.11, 12, 13 A water sample from a cooling tower in our hospital showed growth of Legionella bacteria. Although most patients had no exposure history in our hospital and had pneumonia outside the hospital, the contaminated water system was a probable source of the outbreak. The outbreak of Legionnaires' disease occurred during the COVID-19 pandemic, and the strict control policy implemented for COVID-19 made the community outbreak of Legionnaires' disease unusual. In mid-May 2021, the Taiwan government ordered that all civilians must wear face masks when in any public space, including outdoors, and all swimming pools, water parks, spas, or entertainment places were ordered to be closed. Several reports mentioned that Legionnaires’ disease cases may increase in recently reopened buildings during the COVID-19 pandemic, probably due to growth of Legionella in low-flow water pipes with inadequate disinfection.14, 15, 16 However, this was not the situation of our cluster. After decontamination of the water cooling towers and cisterns in the potential sources, no additional cases were reported. Clinical manifestations may be indistinguishable between COVID-19 and Legionnaires' disease. During the COVID-19 pandemic, all pneumonia patients must be admitted via ER to isolated wards, and tested for COVID-19 repeatedly. The American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) guidelines for community-acquired pneumonia recommend that only severe cases be tested with Legionella urinary antigen test or those with epidemiological indications, and our first six cases required more days for diagnosis and initiation of treatment for Legionnaires' disease than the cases that followed. Cases 2 and 5 needed mechanical ventilator use, and Legionnaires' disease was tested and confirmed after respiratory failure. When the outbreak was observed, we informed clinicians at ER and wards to perform Legionella urinary antigen tests for all pneumonia patients, and this helped to shorten the time for diagnosis. Early empiric use of fluoroquinolones or macrolides to cover suspected Legionnaires’ cases was also carried out based on ATS/IDSA guidelines, and most cases detected later had adequate regimens on the first or second hospital days. Finally, all 15 cases were discharged with pneumonia resolution. In prior studies of community-acquired Legionnaires’ disease in Taiwan, the mortality rates ranged from 9.8% to 24.1%, and ventilator use rates ranged from 18.4% to 50%. , 18, 19, 20, 21 The characteristics, comorbidities, and initial presentations of our cases were similar to those reported in previous studies. Most patients were older adult males with underlying diseases, including diabetes mellitus, hypertension, or malignancy. Fever, cough, and gastrointestinal upset were common, with abnormal laboratory findings, including leukocytosis, hyponatremia, increasing liver enzymes, and high CRP levels. Smoking history was common in prior studies , 18, 19, 20, 21; however, only one case among those in the present study had smoking history. Among studies in Taiwan, about 70% of patients had bilateral pneumonia, , but other studies showed that the most common pattern was patchy, unilobar infiltrate progressing to consolidation of the lung tissue. , Compared with other studies in Taiwan, patients in the present study had lower rates of mortality and ventilator use, and most cases (10/15, 66.7%) had unilateral pneumonia. With proactive screening for Legionnaires’ disease during the outbreak, more cases may be detected with minor severity or at an early stage than prior studies in Taiwan. Besides, most of our cases (11/15, 73.3%) received azithromycin or levofloxacin on the first or second hospital day, and a prior study had a 24-h delayed treatment rate of 50% (16/32), which was associated with a higher proportion (11/16 [68.7%]) of intensive care unit admission and mechanical ventilation than among patients with adequate initiation of treatment (5/16 [31.2%]). Legionnaires' disease accounts for 2%–9% of pneumonia patients , ; however, the exact incidence worldwide may be underestimated mainly because of underdiagnosis and under-reporting. , Detection of clusters of Legionnaires' disease needs clinicians’ awareness and understanding of the clinical characteristics of Legionnaires' disease, sound disease reporting, notification and investigation systems. Severe L. pneumophila pneumonia is associated with high rates of mortality and intensive care unit admission. , 18, 19, 20, 21 , Early, targeted therapy improves outcomes, , and timely investigation and intervention for potential sources limit the scale and recurrence of outbreaks. This study has several limitations. First, blood and respiratory samples were not collected from these cases for culture and isolation, and serogroup or sequence-based typing was not performed. Therefore, we do not know if these cases were caused by the same strain, or whether the strain detected in the cooling tower in our hospital was at cause. Another important challenge was the lack of comprehensive investigation of potential sources. Water samples were only collected from our hospital and buildings A and B, and other public and private construction sites or water systems in this area were not investigated. As a result, some potential sources may have been overlooked.

Conclusions

In conclusion, this study examined and reported a community outbreak of Legionnaires' disease in the neighborhood around our hospital. COVID-19 testing was repeated frequently before testing for Legionnaires' disease during the COVID-19 pandemic. Early recognition of Legionnaires’ disease, detecting the outbreak, and providing timely treatment and intervention improved the individual and overall outcomes.

Declaration of competing interest

The authors declare that they have no competing interests. No funding sources had any role in the design or conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.
  24 in total

1.  A Large Community Outbreak of Legionnaires' Disease Associated With a Cooling Tower in New York City, 2015.

Authors:  Don Weiss; Christopher Boyd; Jennifer L Rakeman; Sharon K Greene; Robert Fitzhenry; Trevor McProud; Kimberlee Musser; Li Huang; John Kornblum; Elizabeth J Nazarian; Annie D Fine; Sarah L Braunstein; Daniel Kass; Keren Landman; Pascal Lapierre; Scott Hughes; Anthony Tran; Jill Taylor; Deborah Baker; Lucretia Jones; Laura Kornstein; Boning Liu; Rodolfo Perez; David E Lucero; Eric Peterson; Isaac Benowitz; Kristen F Lee; Stephanie Ngai; Mitch Stripling; Jay K Varma
Journal:  Public Health Rep       Date:  2017-01-31       Impact factor: 2.792

Review 2.  Legionellosis.

Authors:  J E Stout; V L Yu
Journal:  N Engl J Med       Date:  1997-09-04       Impact factor: 91.245

3.  Legionnaires' disease at a medical center in southern Taiwan.

Authors:  Tzu-Lun Hung; Ming-Chi Li; Li-Rong Wang; Ching-Chuan Liu; Chia-Wen Li; Po-Lin Chen; Ling-Shan Syue; Nan-Yao Lee; Wen-Chien Ko
Journal:  J Microbiol Immunol Infect       Date:  2016-12-18       Impact factor: 4.399

4.  A community outbreak of Legionnaires' disease: evidence of a cooling tower as the source.

Authors:  M Sabria; J Alvarez; A Dominguez; A Pedrol; G Sauca; L Salleras; A Lopez; M A Garcia-Nuñez; I Parron; M P Barrufet
Journal:  Clin Microbiol Infect       Date:  2006-07       Impact factor: 8.067

Review 5.  Legionnaires' disease.

Authors:  Burke A Cunha; Almudena Burillo; Emilio Bouza
Journal:  Lancet       Date:  2015-07-28       Impact factor: 79.321

6.  Community-acquired Legionnaires' disease at a medical center in northern Taiwan.

Authors:  Wei-Fang Kao; Jann-Tay Wang; Wang-Huei Sheng; Yee-Chun Chen
Journal:  J Microbiol Immunol Infect       Date:  2017-09-18       Impact factor: 4.399

7.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

8.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

9.  Legionella community-acquired pneumonia (CAP) presenting with spontaneous bilateral pneumothoraces.

Authors:  Burke A Cunha; Francisco Miled Pherez; Yelda Nouri
Journal:  Heart Lung       Date:  2008 May-Jun       Impact factor: 2.210

Review 10.  Considerations for large building water quality after extended stagnation.

Authors:  Caitlin R Proctor; William J Rhoads; Tim Keane; Maryam Salehi; Kerry Hamilton; Kelsey J Pieper; David M Cwiertny; Michele Prévost; Andrew J Whelton
Journal:  AWWA Water Sci       Date:  2020-08-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.